---
title: "ALX Oncology’s ASPEN-09 Study: A Promising Update for Cancer Treatment"
description: "ALX Oncology is conducting the ASPEN-09 study, a Phase 1b/2 trial evaluating the efficacy and safety of evorpacept combined with anti-cancer therapies for advanced malignancies, including HER2+ breast"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262957330.md"
published_at: "2025-10-27T20:33:34.000Z"
---

# ALX Oncology’s ASPEN-09 Study: A Promising Update for Cancer Treatment

> ALX Oncology is conducting the ASPEN-09 study, a Phase 1b/2 trial evaluating the efficacy and safety of evorpacept combined with anti-cancer therapies for advanced malignancies, including HER2+ breast cancer, colorectal cancer, and head and neck cancer. The study began on May 22, 2025, and is actively recruiting participants. This promising update may positively influence ALX Oncology's stock performance and investor sentiment, given the potential benefits of evorpacept in cancer treatment. Further details can be found on the ClinicalTrials portal.

Alx Oncology Holdings, Inc. is conducting a clinical study titled ‘ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies.’ The study aims to evaluate the efficacy, safety, and tolerability of evorpacept combined with anti-cancer therapies in patients with advanced or metastatic malignancies, focusing on substudies for metastatic HER2+ breast cancer, colorectal cancer, and head and neck cancer.

The intervention being tested is evorpacept, an intravenous drug administered every three weeks, in combination with trastuzumab and chemotherapy. This combination is intended to enhance treatment outcomes in patients with specific types of advanced cancers.

The study follows an interventional design with a sequential intervention model, meaning treatments are applied in a specific order. There is no masking involved, and the primary purpose is treatment-focused.

The study began on May 22, 2025, with the latest update submitted on September 3, 2025. These dates are crucial as they indicate the study’s progress and current status, which is actively recruiting for the breast cancer substudy.

This update could positively impact ALX Oncology’s stock performance and investor sentiment, given the potential of evorpacept to improve cancer treatment outcomes. Investors should also consider the competitive landscape, as advancements in cancer therapies are highly sought after in the pharmaceutical industry.

The ASPEN-09 study is ongoing, with further details available on the ClinicalTrials portal.

### Related Stocks

- [ALXO.US - ALX Oncology](https://longbridge.com/en/quote/ALXO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference \| ALXO Stock News | ALX Oncology Holdings Inc. (Nasdaq: ALXO) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 1 | [Link](https://longbridge.com/en/news/271960009.md) |
| 10:02 ETThe Center for Cancer and Blood Disorders Revolutionizes the Delivery of CAR-T Cancer Treatments for Texas Patients | The Center for Cancer and Blood Disorders has launched a program to deliver CAR-T therapy in community practices across  | [Link](https://longbridge.com/en/news/276139832.md) |
| RISING CANCER RATES AND A PROMISING CANCER TREATMENT | The rising cancer rates among younger Americans, highlighted by the death of actor James Van Der Beek from colorectal ca | [Link](https://longbridge.com/en/news/276298689.md) |
| 11:03 ETNew Guidelines from NCCN Detail Fundamental Differences in Cancer in Children Compared to Adults | The National Comprehensive Cancer Network (NCCN) has released new Clinical Practice Guidelines for Pediatric Soft Tissue | [Link](https://longbridge.com/en/news/276145789.md) |
| 08:09 ETFirst Ascent Biomedical Opens FPM Cancer Lab in Miami; Welcomes World-Class Clinical Leadership | First Ascent Biomedical has opened a Functional Precision Medicine (FPM) laboratory in Miami, now accepting patient refe | [Link](https://longbridge.com/en/news/276058692.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.